Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals, Inc. reports news on the commercialization of PALSONIFY and the development of therapies for endocrine diseases and endocrine-related tumors. The company’s lead product, PALSONIFY (paltusotine), is a once-daily oral treatment approved for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. Recurring updates include product revenue, commercial launch activity, regulatory approvals and submissions, and financial results.
Crinetics’ pipeline news also covers paltusotine in carcinoid syndrome associated with neuroendocrine tumors, atumelnant in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682 for SST2-expressing neuroendocrine tumors and other solid tumors. The company also reports discovery work involving GPCR-targeted small molecules and other endocrine targets.
Crinetics Pharmaceuticals (Nasdaq: CRNX) submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY (paltusotine) to treat acromegaly in adults on March 26, 2026. The filing is supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. PALSONIFY is already approved in the US and recently received a positive CHMP opinion in Europe.
Crinetics Pharmaceuticals (Nasdaq: CRNX) reported Q4 and full-year 2025 results highlighting the commercial launch of PALSONIFY, with $5.4M net product revenue in Q4 and total revenue of $7.7M for 2025. Cash totaled $1.0B at year-end; a Jan 8, 2026 offering added ~$380M. Management expects 2026 GAAP operating expenses of $600–$650M and non-GAAP operating expenses of $480–$520M. Key clinical milestones include EMA CHMP positive opinion for PALSONIFY and initiation plans for an atumelnant Phase 2/3 study in H1 2026.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced management will participate in two investor conferences in March 2026. A fireside chat is scheduled at the TD Cowen Health Care Conference on March 4, 2026 at 1:50 p.m. ET and management will hold 1x1 meetings at both TD Cowen and Leerink on March 4 and March 11, 2026. Live and archived webcasts will be available on the company's Events & Presentations page at www.crinetics.com/events.
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after market close.
Management will host a conference call and webcast the same day at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers and an access code are provided for domestic and international participants, and a live webcast will be available and later archived on the company’s Investor Relations website.
Crinetics (Nasdaq: CRNX) announced dosing of the first patient in the BALANCE-CAH Phase 2/3 trial of atumelnant, a once-daily oral ACTH receptor antagonist for children and adolescents with classic congenital adrenal hyperplasia (CAH).
The potential registrational study will assess safety, efficacy, and pharmacokinetics across three parts: Phase 2 dose-ranging (Part A), Phase 3 double-blind randomized placebo-controlled confirmatory (Part B), and an open-label extension (Part C). The drug holds U.S. orphan drug designation for classic CAH.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that on January 10, 2026 its Compensation Committee granted inducement equity awards to 10 new non-executive employees under the 2021 Inducement Plan.
The grants consist of 37,575 non-qualified stock options and 25,525 restricted stock units (RSUs). Options have an exercise price of $53.25, equal to the Jan. 9, 2026 closing price. Options vest over four years with 25% at the one-year anniversary and the remainder in 36 equal monthly installments; RSUs vest in four equal annual installments, each subject to continued employment.
The awards were made as inducements material to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the 2021 Inducement Plan and applicable award agreements.
Crinetics Pharmaceuticals (Nasdaq: CRNX) priced an underwritten public offering of 7,620,000 common shares at $45.95 per share, generating gross proceeds of approximately $350 million. The underwriters have a 30-day option to purchase an additional 1,143,000 shares. The offering is expected to close on or about January 8, 2026, subject to customary closing conditions.
Crinetics intends to use net proceeds, together with existing cash and investments, to fund the commercial launch of PALSONIFY, research and development of product candidates, other research programs, general corporate purposes, and potentially in-license or acquire complementary assets, although no commitments currently exist. Joint bookrunning managers include Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor; Baird is lead manager.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on January 5, 2026 its intent to sell $350.0 million of common stock in an underwritten public offering, with a 30-day underwriter option to purchase up to an additional $52.5 million of shares. All shares will be sold by the company and the offering is subject to market and other conditions with no assurance of completion.
Crinetics intends to use net proceeds, together with existing cash and investments, to fund the PALSONIFY™ commercial launch, R&D, other research programs, general corporate purposes, and potentially in-license or acquire complementary assets; it has no current commitments to do so. Joint bookrunners include Leerink, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor. The offering is being made from an effective shelf registration; a prospectus supplement will be filed with the SEC.
Crinetics (Nasdaq: CRNX) reported unaudited PALSONIFY U.S. net product revenue of >$5 million for Q4 2025 and early commercial traction with >200 enrollment forms and >125 unique prescribers as of Dec 31, 2025.
In Phase 2 TouCAHn cohort 4, atumelnant 80 mg produced a mean 67% reduction in morning androstenedione (A4) at week 12 and enabled 88% of completers to reduce glucocorticoid doses to physiologic levels; no hepatic transaminase adverse events were observed.
Crinetics Pharmaceuticals (Nasdaq: CRNX) will host a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide a PALSONIFY (paltusotine) commercialization update and to disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia (CAH).
The event includes prepared remarks followed by a live Q&A. A live audio-only webcast will be available and an archived webcast will be posted on the company's Events & Presentations page at www.crinetics.com/events. Dial-in numbers: 1-833-470-1428 (U.S.) or 1-646-844-6383 (international); Access Code: 640078.